These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 28415924

  • 1. An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions.
    Emadi SA, Hammoudeh M, Mounir M, Mueller RB, Wells AF, Sarakbi HA.
    J Int Med Res; 2017 Apr; 45(2):733-743. PubMed ID: 28415924
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A, Poil AR, Hammoudeh M.
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [Abstract] [Full Text] [Related]

  • 3. Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE).
    Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E.
    PLoS One; 2021 Jan; 16(11):e0259389. PubMed ID: 34780502
    [Abstract] [Full Text] [Related]

  • 4. A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.
    Edel Y, Sagy I, Pokroy-Shapira E, Oren S, Dortort Lazar A, Egbaria M, Shiber S, Tal BS, Molad Y.
    Isr Med Assoc J; 2020 Mar; 22(3):154-159. PubMed ID: 32147979
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 6. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
    Direskeneli H, Akkoç N, Bes C, Cakir N, Cefle A, Cobankara V, Dalkilic E, Dinc A, Ertenli I, Gul A, Hamuryudan V, Inanc M, Kalyoncu U, Karaaslan Y, Kasifoglu T, Keser G, Keskin G, Kisacik B, Kiraz S, Masatlioglu S, Onat AM, Ozbek S, Ozturk MA, Pamuk ON, Pay S, Pirildar T, Sayarlioglu M, Senel S, Senturk T, Tasan D, Terzioglu E, Yazici A, Yucel E.
    Clin Exp Rheumatol; 2014 Dec; 32(4):477-83. PubMed ID: 24960289
    [Abstract] [Full Text] [Related]

  • 7. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review.
    Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS.
    J Rheumatol; 2020 Feb; 47(2):176-187. PubMed ID: 30988125
    [Abstract] [Full Text] [Related]

  • 8. [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis].
    Willeke P, Becker H, Wassenberg S, Pavenstädt H, Jacobi AM.
    Z Rheumatol; 2011 Apr; 70(3):232-4, 236-8. PubMed ID: 21359555
    [Abstract] [Full Text] [Related]

  • 9. A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study.
    De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, Elewaut D, Be-Raise study group.
    PLoS One; 2016 Apr; 11(11):e0166607. PubMed ID: 27893771
    [Abstract] [Full Text] [Related]

  • 10. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W.
    J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Recent-Onset Arthritis Disability questionnaire with the Health Assessment Questionnaire disability index in patients with rheumatoid arthritis.
    Salaffi F, Ciapetti A, Gasparini S, Migliore A, Scarpellini M, Corsaro SM, Laganà B, Mozzani F, Varcasia G, Pusceddu M, Castriotta M, Serale F, Maier A, Foti R, Scarpa R, Bombardieri S, NEW INDICES Study Group.
    Clin Exp Rheumatol; 2010 Oct; 28(6):855-65. PubMed ID: 21122262
    [Abstract] [Full Text] [Related]

  • 12. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).
    Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF.
    Ann Rheum Dis; 2014 Jan; 73(1):69-74. PubMed ID: 23904473
    [Abstract] [Full Text] [Related]

  • 13. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study.
    Marras C, Monteagudo I, Salvador G, de Toro FJ, Escudero A, Alegre-Sancho JJ, Raya E, Ortiz A, Carmona L, Mestre Y, Cea-Calvo L, Calvo-Alén J.
    Rheumatol Int; 2017 Jul; 37(7):1195-1202. PubMed ID: 28516236
    [Abstract] [Full Text] [Related]

  • 14. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, Vlahos B, Pedersen R, Singh A.
    BMC Musculoskelet Disord; 2013 Jan 08; 14():13. PubMed ID: 23294908
    [Abstract] [Full Text] [Related]

  • 15. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
    Kivitz A, Olech E, Borofsky MA, Zazueta B, Navarro-Sarabia F, Radominski SC, Merrill JT, Pacheco-Tena C, Pei J, Nasmyth-Miller C, Pope JE.
    J Rheumatol; 2018 Apr 08; 45(4):456-464. PubMed ID: 29247149
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug 08; 60(8):2262-71. PubMed ID: 19644846
    [Abstract] [Full Text] [Related]

  • 17. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr 08; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 18. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S, Mohanty M, Padhan P.
    Indian J Pharmacol; 2015 Apr 08; 47(6):605-9. PubMed ID: 26729950
    [Abstract] [Full Text] [Related]

  • 19. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 08; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 20. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM.
    Clin Rheumatol; 2017 Jun 08; 36(6):1395-1400. PubMed ID: 28255739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.